PRAKASH, SATYA,JONES, MITCHELL, LAWRENCE,MARTONI, CHRISTOPHER
申请号：
EP10769192
公开号：
EP2419114A4
申请日:
2010.04.30
申请国别(地区):
EP
年份:
2013
代理人:
摘要：
The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof； wherein the highly bsh active bacteria degrades >；50µmol glycodeoxycholic acid (GDCA)/gram/hour and >；2µmol taurodeoxycholic acid (TDCA)/gram/hour when measured over 1 hour and 5 hours, respectively, or degrades >；65 µmol GDCA/g/hr and >；7 µmol TDCA/g/hr when measured over 30 minutes.
